Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Anatomy of periprostatic nerves and nerve-sparing strategy for radical prostatectomy
Qiancheng Ma; Yan Liu; Yongzheng Han; Qiwei Chen; Deyong YangShow moreShow less
1. Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China; 2. Dalian Medical University, Dalian, China; 3. Department of Surgery, Healinghands Clinic, Dalian, ChinaShow moreShow less
Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)
Young Suk Kwon; Reena Kudchadker; Neil B. Desai; Raquibul Hannan; MinJae Lee; Ryan Mauck; Jennifer Tse; Kris Gaston; Tamara Dickinson; Shaghayegh Rezaie; Brad Hornberger; Daniel Yang; Maricruz Ibarra; Howard Morgan; Yang Kyun Park; Yesenia Gonzalez; Claus Roehrborn; Robert Timmerman; Solomon Woldu; Aurelie GarantShow moreShow less
1. Department of Radiation Oncology, University of Texas at Southwestern Medical Center, Dallas, USA; 2. Division of Clinical & Translational Sciences, McGovern Medical School, UTHealth Houston, Houston, USA; 3. Department of Urology, University of Texas at Southwestern Medical Center, Dallas, USA; 4. CARTI, Little Rock, USAShow moreShow less
Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177 Lu-PSMA-617 therapy in advanced prostate cancer
Ronit Juthani; Caiwei Zhong; Ali Tarhini; Miguel Muniz; Wanling Xie; Hailey Stoltenberg; Andrew Wolanski; Jolivette Ritzer; Xiao X. Wei; Heather Jacene; Daniel S. Childs; Praful RaviShow moreShow less
1. St Vincent’s Hospital, Worcester, USA; 2. Dana-Farber Cancer Institute, Boston, USA; 3. Department of Oncology, Mayo Clinic, Rochester, USAShow moreShow less
PRAISE-U: from pilot to program—what clinicians need to know from population-based screening for prostate cancer
M. J. Roobol; R. C. N. van den Bergh; S. Collen; A. Chandran; H. Van PoppelShow moreShow less
1. Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; 2. European Association of Urology, Policy Office, Arnhem, The Netherlands; 3. International Agency for Research on Cancer/World Health Organization, Lyon, France; 4. Department of Urology, KU Leuven, Leuven, BelgiumShow moreShow less
Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study
Rana R. McKay; Orsolya Lunacsek; Matthew J. Korn; Amit D. RavalShow moreShow less
1. Moores Cancer Center, University of California San Diego, La Jolla, USA; 2. Bayer HealthCare Pharmaceuticals, Whippany, USAShow moreShow less
Prostate cancer worldwide: updated epidemiology, disparities, and screening implications
Rui M. Bernardino; David-Dan Nguyen; Sigrid V. Carlsson; Giorgio Gandaglia; Zeyad Schwen; Nicolas A. Soputro; Mohamad Watfa; Abdulrahman Al-Bayati; Mohammad El Hussein; Rebecca Campbell; Karim Daher; Salim Younis; Jane Nguyen; Christopher Weight; Carlo La Vecchia; Alexandre R. Zlotta; Cosimo de Nunzio; Firas Abdollah; Jonathan Evan Shoag; Spyridon Basourakos; Frederico Ferronha; Andrea Cosenza; Christopher Wallis; Quoc-Dien Trinh; Neil Fleshner; Jihad Kaouk; Riccardo AutorinoShow moreShow less
1. Glickman Urological Institute, Cleveland Clinic, Cleveland, USA; 2. Division of Urology, University of Toronto, Toronto, Canada; 3. Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany; 4. Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden; 5. Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; 6. Diagnostics Institute, Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, USA; 7. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; 8. Department of Urology, Sant’Andrea Hospital, ‘Sapienza’ University of Rome, Rome, Italy; 9. Vattikuti Urology Institute, Henry Ford Health System, Detroit, USA; 10. University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, USA; 11. Unidade Local Saúde São José, Lisbon, Portugal; 12. University of Pittsburgh School of Medicine, Pittsburgh, USAShow moreShow less
FAQ
How long does PROSTATE CANCER AND PROSTATIC DISEASES take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for PROSTATE CANCER AND PROSTATIC DISEASES. The fastest paper went from submission to acceptance in 2 days (Focal therapy for localized prostate cancer: not all that glitters is gold, received 2026-06-15, accepted 2026-06-17); the slowest took 246 days. The average is 112.7 days and the median is 127.5 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
